# OnCo record nct06157892 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06157892/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06157892", "NCT06157892" ;
  schema:name "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors"@en ;
  schema:description "A phase 2 trial of Disitamab vedotin and Tucatinib in gastric & gastro-oesophageal junction cancer, HER2-positive breast cancer and triple-negative breast cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06157892/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06157892> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2024-05-20" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/tnbc/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/disitamab-vedotin/>, <https://onco.cc/drugs/tucatinib/> ;
  onco:companies <https://onco.cc/companies/remegen/> .